Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dobesilic Acid SCHEMBL27684460 | 0.98 | LMNA (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL27682792 | 0.98 | HSD17B10 (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL27682884 | 0.98 | HSD17B10 (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL27703351 | 0.98 | LMNA (0.68) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL232087 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL29389625 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL214799 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL15364076 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL78224 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL9790423 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105837825-B | Fire retardant and its preparation method and application for polycarbonate | 中蓝晨光化工研究设计院有限公司 | 2019-02-01 | — | — | CN | claimed |
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | DERMACT PHARMACEUTICAL, INC. | 2018-03-22 | — | — | US | claimed |
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | AmDerma Pharmaceuticals, LLC | 2017-08-17 | — | — | US | claimed |
| US-9610256-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer | AmDerma Pharmaceuticals, LLC (US) | 2017-04-04 | — | — | US | claimed |
| CN-105837825-A | Flame retardant for makrolon and preparation method and application thereof | 中蓝晨光化工研究设计院有限公司 | 2016-08-10 | — | — | CN | claimed |
| US-9301931-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | AmDerma Pharmaceuticals, LLC (US) | 2016-04-05 | — | — | US | claimed |
| US-20160058719-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | Lichten, Edward | 2016-03-03 | — | — | US | claimed |
| US-20150065584-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | AmDerma Pharmaceuticals, LLC | 2015-03-05 | — | — | US | claimed |
| US-8912171-B2 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | AmDerma Pharmaceuticals, LLC (US) | 2014-12-16 | — | — | US | claimed |
| US-20130296282-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | AmDerma Pharmaceuticals, LLC | 2013-11-07 | — | — | US | claimed |
| EP-2054051-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | Investread Europe, S.L. (ES) | 2009-05-06 | — | — | EP | claimed |
| US-20090111779-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2009-04-30 | — | — | US | claimed |
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ACTION MEDICINES (ES) | 2008-05-29 | — | — | US | claimed |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | ACTION MEDICINES (ES) | 2008-05-15 | — | — | US | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020025-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| CN-101081824-A | 2,5-dihydroxy benzenes sulfonic acid magnesium and hydrate thereof | ZHENHUA HUANG (CN) | 2007-12-05 | — | — | CN | claimed |
| US-20070149618-A1 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | ACTION MEDICINES, S.L. | 2007-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125485-A1 | 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis | ARSA, CYP8B1, EBP | LMNA 2761/4885HSD17B10 14/4885HPGD 365/4885 |
| US-20160058719-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20090111779-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20150065584-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20170231932-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20080114063-A1 | Use of 2,5-Dihydroxybenzene Derivatives for the Treatment of Tissue Reactive Diseases | CYP11B1, CYP11B2, MYLK | LMNA 741/4885HSD17B10 70/4885HPGD 125/4885 |
| US-20130296282-A1 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20070149618-A1 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20180078495-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ABCB11, KCNK5, KCNQ5 | LMNA 3019/4885HSD17B10 2486/4885HPGD 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.